Breakdown | ||||
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
6.57B | 6.47B | 6.50B | 5.91B | 5.49B | Gross Profit |
1.38B | 1.37B | 1.29B | 1.20B | 1.20B | EBIT |
252.92M | 275.97M | 157.00M | 210.61M | 126.44M | EBITDA |
374.76M | 386.14M | 367.17M | 301.75M | -476.90M | Net Income Common Stockholders |
185.93M | 207.56M | 203.21M | 155.98M | -589.37M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
114.46M | 159.67M | 142.01M | 143.24M | 77.94M | Total Assets |
2.90B | 2.88B | 2.74B | 2.75B | 2.72B | Total Debt |
762.94M | 628.00M | 590.23M | 721.87M | 668.33M | Net Debt |
648.48M | 468.33M | 448.22M | 578.62M | 590.38M | Total Liabilities |
1.90B | 1.76B | 1.70B | 1.79B | 1.88B | Stockholders Equity |
1.00B | 1.12B | 1.04B | 964.67M | 836.44M |
Cash Flow | Free Cash Flow | |||
-857.00M | -819.07M | -1.02B | -756.31M | -285.35M | Operating Cash Flow |
-789.38M | -754.85M | -980.99M | -730.52M | -243.54M | Investing Cash Flow |
959.54M | 901.57M | 1.24B | 810.66M | 499.13M | Financing Cash Flow |
-215.91M | -126.48M | -253.23M | -22.64M | -271.23M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $88.78B | 32.47 | 51.23% | 0.39% | 14.29% | -1.20% | |
75 Outperform | $10.63B | 24.64 | 10.85% | 7.24% | 9.90% | 56.41% | |
70 Outperform | $2.77B | 20.21 | 14.15% | 2.49% | -0.85% | -23.40% | |
69 Neutral | $8.00B | 21.39 | 11.07% | ― | 2.71% | -3.26% | |
68 Neutral | $48.37B | 28.04 | 5.97% | 2.36% | 5.84% | 15.12% | |
68 Neutral | $35.69B | 27.91 | -43.80% | 1.35% | 2.85% | 110.82% | |
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% |
On April 22, 2025, Patterson Companies announced the completion of its acquisition by Patient Square Capital, a healthcare investment firm, which resulted in the company’s stock no longer being traded on the NASDAQ Global Select Market. Concurrently, Robert Rajalingam was appointed as the new CEO, succeeding Don Zurbay, who will continue to support the company during the transition. Rajalingam, with over 25 years of healthcare management experience, is expected to drive operational excellence and strategic growth, enhancing Patterson’s offerings and partnerships.
Spark’s Take on PDCO Stock
According to Spark, TipRanks’ AI Analyst, PDCO is a Neutral.
Patterson Companies scores well due to its stable operational efficiency and strong market momentum. However, challenges with profitability and cash flow management slightly dampen its overall performance. The stock’s valuation is fair, and its dividend yield is a positive aspect for investors seeking income. Technical indicators suggest strong momentum, though caution is advised due to potential overbought conditions.
To see Spark’s full report on PDCO stock, click here.
Patterson Companies, Inc. has completed significant financial restructuring by repaying and terminating its existing credit and financing agreements as of the closing date. In a major corporate development, the company has undergone a merger, resulting in its common stock being delisted from Nasdaq and a reorganization of its board of directors, with several resignations and new appointments. The merger also led to amendments in the company’s articles of incorporation and bylaws.
Spark’s Take on PDCO Stock
According to Spark, TipRanks’ AI Analyst, PDCO is a Neutral.
Patterson Companies scores well due to its stable operational efficiency and strong market momentum. However, challenges with profitability and cash flow management slightly dampen its overall performance. The stock’s valuation is fair, and its dividend yield is a positive aspect for investors seeking income. Technical indicators suggest strong momentum, though caution is advised due to potential overbought conditions.
To see Spark’s full report on PDCO stock, click here.